mTOR inhibition in COVID‐19: A commentary and review of efficacy in RNA viruses
Karam BS, Morris RS, Bramante CT, Puskarich M, Zolfaghari EJ, Lotfi‐Emran S, Ingraham NE, Charles A, Odde DJ, Tignanelli CJ. mTOR inhibition in COVID‐19: A commentary and review of efficacy in RNA viruses. Journal Of Medical Virology 2020, 93: 1843-1846. PMID: 33314219, PMCID: PMC8159020, DOI: 10.1002/jmv.26728.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntiviral AgentsCOVID-19COVID-19 Drug TreatmentHumansMiddle East Respiratory Syndrome CoronavirusRNA VirusesSARS-CoV-2Signal TransductionTOR Serine-Threonine KinasesVirus ReplicationConceptsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionCoronavirus 2 infectionReview of efficacyCoronavirus disease 2019Modulation of mTORSARS-CoV-2RNA virusesDisease 2019Recent evidence pointsMTOR inhibitorsViral infectionMTOR inhibitionMTOR pathwayMammalian targetRapamycin (mTOR) pathwayNumerous RNA virusesVirus growthCOVID-19MTOR resultsInfectionCurrent literatureHighlight evidenceEvidence points